Clinical Trial Results for Sjögren’s Syndrome Treatment

This report discusses the early clinical trial results for a new treatment targeting Sjögren’s syndrome, a condition often misunderstood and neglected. The trial, led by rheumatologist Benjamin Fisher, involved the experimental drug CFZ533, which aims to address the underlying causes of the disease rather than just its symptoms. The trial focused on patients with severe primary Sjögren’s syndrome and measured the drug's effectiveness using the EULAR Sjögren’s syndrome disease activity index (ESSDAI). Results indicated a mean reduction of 5.6 points in ESSDAI scores among patients receiving the higher dose of CFZ533. The report outlines the challenges in diagnosing Sjögren’s syndrome and the unmet need for effective therapies. It also highlights the collaboration between Novartis researchers and specialized medical centers to advance understanding and treatment of the disease. The findings were presented at the American College of Rheumatology Annual Meeting, and further testing of CFZ533 is planned to confirm these initial results.